Signatera Publications

Bladder Cancer | Breast Cancer | Colorectal Cancer | Other GastroIntestinal Malignancies | Genitourinary (GU) Cancer | Head and Neck Cancer | Lung Cancer
Melanoma | Merkel Cell Carcinoma | Multiple Myeloma | Ovarian Cancer | Pancancer | Pancreatic Cancer | Sarcoma

Bladder Cancer

1. 2023: Lars NAC vs NoNAC cohort | Open access
   Lindskrog SV, Birkenkamp-Demtroder K, Nordentoft I, et al. Circulating tumor DNA analysis in advanced urothelial carcinoma: insights from biological analysis and extended clinical follow-up. Clinical Cancer Research. 2023; Oct 2. doi: 10.1158/1078-0432.CCR-23-1860
2. 2023: IMvigor010 updated OS analysis | Not Open Access
   Powles T, Assaf ZA, Degaonkar V, et al. Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma. European Urology. 2023; doi: 10.1016/j.eururo.2023.06.007
3. 2022: ABACUS-GNE | Open Access
   Szabados B, Kockx M, Assaf ZA, et al. Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder. European Urology. 2022; 82, 212-222
4. 2021: MIUC-Nature | Open Access
   Powles T, Assaf ZA, Davarpanah N, et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature. 2021; 82, 212-222
5. 2019: Christensen JCO | Open Access
   Christensen E, Birkenkamp-Demtroder K, Sethi H, et al. Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma. Journal of Clinical Oncology. 2019: 37(18):1547-1557

Breast Cancer

1. 2023: I-SPY2 | Open Access
   Magbanua MJM, Swigart LB, Ahmed Z, et al. Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy. Cancer Cell. 2023;41(6):1091-1102.
2. 2022: Beyond BRCA | Open Access
   Gruber JJ, Afghani A, Timss K, et al. A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes. Nature Cancer. 2022; https://doi.org/10.1038/s43018-022-00439-1
3. 2022: Neoadjuvant Chemotherapy | Open Access
   Cailleux F, Agostinetto E, Lambertini M, et al. Circulating tumor DNA after neoadjuvant chemotherapy in breast cancer is associated with disease relapse. JCO-Precision Oncology. 2022; 6: e2200148.
   Correspondence: Cappelletti V, Pruneri G, Cosimo SD. Advancing circulating tumor DNA for recurrent breast cancer. JCO-Precision Oncology. doi.org/10.1200/PO.22.00596
   Response: Agostinetto E, Kalshnikova E, Ignatiadis M, et al. Reply to Di Cosimo et al.: Advancing circulating tumor DNA for recurrent breast cancer. JCO-Precision Oncology doi.org/10.1200/PO.22.00644.
4. 2022: TNBC Case Report | Open Access
   Azzi G, Krinshpun S, Tin A, et al. Treatment response monitoring using a tumor-informed circulating tumor DNA test in an advanced triple negative breast cancer patient: A case report. Case Reports in Oncology. 2022;15:473-479.
5. 2021: ISPY ctDNA-imaging | Open Access
   Magbanua MJM, Wen L, Wolf DM, et al. Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk. NPJ Breast Cancer. 2021;7(32):1-8.
6. 2021: ISPY-NAC-Breast | Open Access
   Magbanua MJM, Swigart LB, Wu H-T, et al. Circulating tumor DNA in neoadjuvant treated breast cancer reflects response and survival. Annals of Oncology. 2021;32(2):229-239.
7. 2019: Leicester Breast Study | Open Access
   Coombes C, Page K, Salari R, et al. Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence. Clinical Cancer Research. 2019;25(14):4255-4263.

Colorectal Cancer

1. 2023: CRC Peritoneal Mets | Open Access
   Dhiman A, Kothary V, Witmer HD, et al. Role of Tumor-informed Personalized ctDNA Assay in Informing Recurrence in Patients with Peritoneal Metastases from Colorectal and High-grade Appendix Cancer Undergoing Curative Intent Surgery. Annals of Surgery. 2023 Mar 30. doi: 10.1097/SLA.0000000000005856. Online ahead of print.
2. 2023: CIRCULATE- Galaxy Interim Analysis | Open Access
   Kotani D, Oki E, Nakamura Y, et al. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nature Medicine. 2023;29(1):127-134.
3. 2022: CRC Stage I Case Study | Open Access
   Alden SL, Dhani H, Palsuledesai C, et al. Post-operative ctDNA monitoring in stage I colon cancer: A case report. Frontiers in Oncology. 2022;12:1074786.
4. 2022: CTLA-4 Case series | Open Access
   Kasi PM, Budde G, Krainock M, et al. Circulating tumor DNA (ctDNA) serial analysis during progression on PD-1 blockade and later CTLA-4 rescue in patients with mismatch repair deficient metastatic colorectal cancer. Journal for ImmunoTherapy of Cancer. 2022;10:e003312.
5. 2022: DENEB study-Circulate Japan | Open Access
   Miyo M, Kato T, Nakamura Y, et al. DENEB: Development of a new criteria for curability after local excision of pathological T1 colorectal cancer using liquid biopsy. Cancer Science. 2022; 113:1531-1534.
6. 2021: Liver Metastasis CRC Case Report | Open Access
   Weinberg BA, Winslow ER, Bayasi M, et al. Early detection of circulating tumor DNA post-operatively enables discovery of resectable metastatic disease in a patient with colon cancer. Case reports in Oncology. 2021;14:1748–1753.
7. 2021: Stage III CRC | Open Access
   Henriksen TV, Tarazona N, Frydendahl A, et al. Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, towards assessment of adjuvant therapy efficacy and clinical behavior of recurrences. Clin Cancer Res. 2021; 21-2404.
8. 2021: Bespoke CRC protocol | Open Access
   Kasi PM, Sawyer S, Guilford J, et al. BESPOKE study protocol: A multicenter, prospective observational study to evaluate the impact of circulating tumor DNA guided therapy on patients with colorectal cancer. BMJ Open. 2021;11(9):e047831.
9. 2021: AMAL Predator Study | Open Access
   Loupakis F, Sharma S, Derouazi M, et al. Detection of molecular residual disease using personalized circulating tumor DNA assay in colorectal cancer patients undergoing resection of metastases. JCO-Precision Oncology. 2021; 5:1166-1177.
10. 2021: MSS CRC Case Report | Open Access
    Schneider CJ, Krainock M, Malashevich AK, et al. ctDNA clearance and radiographic resolution of disease in response to dual checkpoint inhibition in metastatic microsatellite stable colorectal cancer with a high tumor mutation burden. Case reports in Oncology. 2021;14:849–853.
11. 2021: GALAXY Protocol | Open Access
    Taniguchi H, Nakamura Y, Kotani D, et al. CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer. Cancer Science. 2021;112:2915–2920.
12. 2019: Aarhus study | Open Access
    Reinert T, Henriksen TV, Christensen E, et al. Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stage I to III Colorectal Cancer. JAMA Oncology. 2019;5(8):1124-1131.
    Correspondence: 2021: Guardant Reveal letter to the editor | Reinert T, Henriksen TV, Aleshin A, et al. Plasma-only ctDNA-guided MRD detection in patients with CRC - Letter. Clinical Cancer Research. 2021;27:6613.

Other GastroIntestinal Malignancies (Esophageal, Anal Squamous Cell)

1. 2023: Appendiceal Cancers | Open Access
   Bhutiani M, Helmink BA, Zeineddine M, et al. Utility of Circulating tumor DNA in Appendiceal Tumors. Journal of Gastrointestinal Surgery. 2023; doi: 10.1007/s11605-023-05825-3
2. 2023: Gastric and Appendiceal Cancers | Not Open Access
   Singh H, Klempner SJ, Melnitchouk N, et al. Highly sensitive circulating tumor DNA assay aids clinical management of radiographically occult isolated peritoneal metastases in patients with GI cancer. JCO-Precision Oncology. 2023; 7:e2200572.
3. 2022: Anal Squamous Cell Carcinoma | Open Access
   Azzi G, Tavallai M, Aushev VA, et al. Using Tumor-Informed Circulating Tumor DNA (ctDNA)-Based Testing for Patients with Anal Squamous Cell Carcinoma. The Oncologist. 2023; 28(3):220-229.
4. 2022: Esophagogastric CLIA Study | Open Access
   Huffman BM, Aushev VN, Budde GL, et al. Analysis of circulating tumor DNA to predict risk of recurrence in patients with esophageal and gastric cancers. JCO-Precision Oncology. 2022; 6:e2200420.
   Correspondence: Chakrabarti S, Mahipal A. Circulating Tumor DNA-guided Recurrence Risk Assessment in Esophageal and Gastric Cancer: Assay Holds the Key. JCO-Precision Oncology. 2023; 7:e2200710.
   Response: Reply to S. Chakrabarti et al. Reply to S. Chakrabarti and A. Mahipal. JCO-Precision Oncology. 2023; 7:e22300043.
5. 2021: Esophageal UK Fitzgerald | Open Access
   Ococks E, Sharma S, Ng AWT, et al. Serial ctDNA detection using a personalized, tumor-informed assay in esophageal adenocarcinoma patients following resection. Gastroenterology. 2021; 161(5):1705-1708.e2.
6. 2020: Esophageal Case Study | Open Access
   Einstein DJ, Liang N, Malhotra M, et al. Assessment of Molecular Remission in Oligometastatic Esophageal Cancer with a Personalized Circulating Tumor DNA Assay. JCO-Precision Oncology. 2020;4:239-243.
7. 2021: Gastrointestinal Malignancies | Open Access
   Zhang S, Brazel D, Kumar P, et al. Utility of tumor-informed circulating tumor DNA in the clinical management of gastrointestinal malignancies. Gastrointestinal Oncology. 2021; doi: 10.21037/jgo-21-484

Genitourinary (GU) Cancer

1. 2023: Advanced GU study | Open Access
   Jang A, Lanka SM, Jaeger EB, et al. Longitudinal Monitoring of Circulating Tumor DNA to Assess the Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Genitourinary Malignancies. JCO Precis Oncol 2023;7:e2300131.

Head and Neck Cancer

1. 2021: PMCC SNOW project | Open Access
   Oliva M, Chepeha D, Araujo D, et al. Antitumor Immune Effects of Pre-operative Sitravatinib and Nivolumab Lead to Major Clinical and Pathological Responses in Oral Cavity Cancer: The SNOW Window of Opportunity Study. Journal for ImmunoTherapy of Cancer. 2021;9(10), e003476.

Lung Cancer

1. 2024: Personalized tumor-informed ctDNA for detecting MRD in NSCLC patients receiving curative treatments | Open Access
   Youjin Oh, et al. Personalized, tumor-informed, circulating tumor DNA assay for detecting minimal residual disease in non-small cell lung cancer patients receiving curative treatments. Thorac Cancer. 2024;1–8.
2. 2024: tDNA for MRD and early recurrence detection in early stage lung cancer | Open Access
   Aaron C. Tan, et al. Detection of circulating tumor DNA with ultradeep sequencing of plasma cell‐free DNA for monitoring minimal residual disease and early detection of recurrence in early‐stage lung cancer. Cancer. 2024,1-8.
3. 2024: Real-world experience monitoring ctDNA in eNSCLC
   Travis K. Martin, et al. Early real-world experience monitoring circulating tumor DNA in resected early-stage non–small cell lung cancer. The Journal of Thoracic and Cardiovascular Surgery 2024.
4. 2023: Bob Li Paper | Open Access
   Lebow E, Shaverdian N, Eichholz JE, et al. ctDNA-based detection of molecular residual disease in stage I-III non-small cell lung cancer patients treated with definitive radiotherapy. Front. Oncol. 2023,13:1253629.
5. 2023: NeoCOAST Trial | Open Access
   Cascone T, Kar G, Spicer JD, et al. Neoadjuvant Durvalumab alone or combined with novel immuno-oncology agents in resectable lung cancer: The Phase 2 NeoCOAST platform trial. Cancer Discov. 2023, https://doi.org/10.1158/2159-8290.CD-23-0436.
6. 2017: Swanton Nature Paper | Open Access
   Abbosh C, Birkbak N, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017,545:446–451.

Melanoma

1. 2024: Physician perspective on biomarker/ctDNA testing in melanoma | Open Access
   Rachel A. Fischer, et al. US physician perspective on the use of biomarker and ctDNA testing in patients with melanoma. Critical Reviews in Oncology / Hematology. 196 (2024) 104289.
2. 2023: CLIA Cohort Study | Open Access
   Brunsgaard EK, Bowles TL, Asare EA, et al. Feasibility of personalized circulating tumor DNA detection in stage II and III melanoma patients. Melanoma Res. 2023;33(3):184-191.
3. 2023: CLIA Cohort Study | Open Access
   Eroglu Z, Krinshpun S, Kalashnikova E, et al. Circulating tumor DNA based molecular residual disease detection for treatment monitoring in advanced melanoma patients. Cancer. 2023;129(11):1723-1734.
4. 2022: Case Report | Open Access
   Khaddour K, Zhou A, Butt OH, et al. Case report: Real-world experience using a personalized cancer-specific circulating tumor DNA assay in different metastatic melanoma scenarios. Front. Oncol. 2022;12: 978996.

Merkel Cell Carcinoma

1. 2022: Research Letter | Open Access
   Park S J, Kannan A, Harris JP NH, et al. Circulating tumor DNA as a predictive biomarker in Merkel cell carcinoma. JAAD Case Report.

   doi: https://doi.org/10.1016/j.jaad.2022.03.020.

2. 2021: Case Report | Open Access
   Yeakel J, Kannan A, Rattigan NH, et al. Bespoke circulating tumor DNA as a biomarker for treatment response in a refractory merkel cell carcinoma patient. JAAD Case Report.

   doi: https://doi.org/10.1016/j.jdcr.2021.10.025.

Multiple Myeloma

1. 2022: Multiple Myeloma | Open Access
   Dhakal B, Sharma S, Balcioglu M et al. Assessment of Molecular Residual Disease Using Circulating Tumor DNA to Identify Multiple Myeloma Patients at High Risk of Relapse. Front. in Oncol. 2022; 12:786451.

Ovarian Cancer

1. 2022: Ovarian Cancer (Hou) | Open Access
   J.Y. Hou, J.S. Chapman, E. Kalashnikova et al. Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer. Gynecologic Oncology. 2022.

Pancancer

1. 2023: Clinical Position Paper | Open Access
   Cohen S, Liu MC, Aleshin A. Practical recommendations for using ctDNA in clinical decision making. Nature. 2023; 619:259-268.
2. 2022: BESPOKE IO Protocol | Open Access
   Kasi PM, Chakrabarti S, Sawyer S, et al. BESPOKE IO protocol: a multicentre, prospective observational study evaluating the utility of ctDNA in guiding immunotherapy in patients with advanced solid tumours. BMJ Open. 2022;12:e060342.
3. 2022: Signatera in Pregnancy | Open Access
   Cohen SA, Kasi A, Hook N, et al. The Utility of Circulating Tumor DNA (ctDNA) Monitoring in Cancer Patients Who Are Pregnant or Planning to Become Pregnant. Case Reports in Obstetrics and Gynecology. 2022:9412201.
4. 2022: MRD in clinical trial Review | Open Access
   Kasi P, Fehringer G, Taniguchi H, et al. Impact of Circulating Tumor DNA-Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors. JCO-PO. 2022;6:e2100181.
   Correspondence: Dayyani F, Senthil M. Spontaneous Fluctuations of Tumor-Informed Circulating Tumor DNA at Low Levels. JCO Precision Oncology no. 6 (2022) e2200177. Published online July 14, 2022.
   Response: Kasi PM, Fehringer G, Aleshin A, et al. Reply to Dayyani F. JCO Precision Oncology no. 6 (2022) e2200275. Published online July 14, 2022.
5. 2021: Genomic Predictors of IO | Open Access
   Yang CSY, Lien SC, Wang BX, et al. Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity. Nat Commun. 2021;12:5137.
6. 2020: cfDNA Surgical Trauma (CRC and Bladder) | Open Access
   Henriksen TV, Reinert T, Christensen T, et al. The effect of surgical trauma on circulating free DNA levels in cancer patients - implications for studies of circulating tumor DNA. Molecular Oncology. 2020;14:1670-1679.
7. 2020: PMCC IO | Not Open Access
   Bratman SV, Yang SYC, Iafolla MAJ, et al. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nature Cancer. 2020.1:873-881.

Pancreatic Cancer

1. 2021: Case Series | Open Access
   Abdelrahim M, Esmail A, Xu J, et al. Early relapse detection and monitoring disease status in patients with early-stage pancreatic adenocarcinoma using circulating tumor DNA. J Surg Res. 2021; 4(4):602-615.

Sarcoma

1. 2022: CLIA Cohort Study | Open Access
   Zhou M, Bui N, Rathore R, et al. Feasibility of longitudinal ctDNA assessments in patients with uterine and extra-uterine leiomyosarcoma. Cancers. 2023; 15, 157.